These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 28185715

  • 1. Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Yabiku K, Mutoh A, Miyagi K, Takasu N.
    Clin Ther; 2017 Mar; 39(3):558-566. PubMed ID: 28185715
    [Abstract] [Full Text] [Related]

  • 2. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
    García Díaz E, Guagnozzi D, Gutiérrez V, Mendoza C, Maza C, Larrañaga Y, Perdomo D, Godoy T, Taleb G.
    Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
    Kinoshita T, Shimoda M, Nakashima K, Fushimi Y, Hirata Y, Tanabe A, Tatsumi F, Hirukawa H, Sanada J, Kohara K, Irie S, Kimura T, Nakamura Y, Nishioka M, Obata A, Nakanishi S, Mune T, Kaku K, Kaneto H.
    J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
    [Abstract] [Full Text] [Related]

  • 4. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, Yuan H, Xiao X, Luo S, Shan Z, Deng H, Tan Y, Xu F, Xu W, Zeng L, Kang Z, Weng J.
    Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
    [Abstract] [Full Text] [Related]

  • 5. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 6. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
    Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, Akiyama Y, Morimoto Y, Noda M, Shimada A.
    Diabetes Care; 2017 Oct; 40(10):1364-1372. PubMed ID: 28751548
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G.
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.
    Lu J, Zang J, Li H.
    PLoS One; 2013 Nov; 8(10):e76713. PubMed ID: 24204660
    [Abstract] [Full Text] [Related]

  • 12. Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Hooshmand Gharabagh L, Shargh A, Mohammad Hosseini Azar MR, Esmaeili A.
    Clin Res Hepatol Gastroenterol; 2024 Mar; 48(3):102279. PubMed ID: 38159676
    [Abstract] [Full Text] [Related]

  • 13. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
    Blazina I, Selph S.
    Syst Rev; 2019 Nov 29; 8(1):295. PubMed ID: 31783920
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F.
    Lancet Diabetes Endocrinol; 2017 May 29; 5(5):341-354. PubMed ID: 28385659
    [Abstract] [Full Text] [Related]

  • 16. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.
    Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, Omata M, Koike K.
    ScientificWorldJournal; 2012 May 29; 2012():496453. PubMed ID: 22927782
    [Abstract] [Full Text] [Related]

  • 17. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.
    Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S, Kawai H, Ohashi N, Mori A.
    Diabetes Obes Metab; 2018 Feb 29; 20(2):438-442. PubMed ID: 28719078
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.